Advertisement

Topics

Latest Respiratory NewsRSS

13:30 EST 23rd January 2019 | BioPortfolio

Northern Virginia Pulmonary and Critical Care Associates Partners with TSI Healthcare

Northern Virginia Pulmonary and Critical Care Associates, located in Falls Church and Annandale, Virginia has partnered with TSI Healthcare, a national leader in the sales and support of customized NextGen® Practice Management (PM) and Electronic Health Record (EHR) solutions. TSI Healthcare will be the sole provider and support center for Northern Virginia Pulmonary and Critical Care Associa...

Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)

CLEVELAND, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated wi...

In Kenya, 70-80% of the population is dependent on wood-based cooking. CISL and @AstraZeneca hope to change this, installing biogas stoves and biodigesters in communities to help reduce respiratory illness & aid conservation efforts: http://ow.ly/XXKR50k

In Kenya, 70-80% of the population is dependent on wood-based cooking. CISL and @AstraZeneca hope to change this, installing biogas stoves and biodigesters in communities to help reduce respiratory illness & aid conservation efforts: http://ow.ly/XXKR50khpdX 

Kaia Health raises $10M for AI apps that treat chronic pain

Kaia Health, a digital therapeutics company based in Munich, Germany, has raised $10 million in a Series A funding round for its apps that use AI and motion-tracking technology to manage chronic back pain and chronic obstructive pulmonary disease (COPD), according to a report by VentureBeat.

Acute Bronchitis Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Acute Bronchitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Acute Bronchitis Global Clinical Trials Review, H2, 2018" provides an overview of Acute Bronchitis clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Bronchitis. Report includes an overview of trial numbers and their average enrollment in top countri...

Germany Respiratory Devices Market Outlook to 2025 [Report Updated: 12102018] Prices from USD $4995

Germany Respiratory Devices Market Outlook to 2025SummaryGlobalData's new report, Germany Respiratory Devices Market Outlook to 2025, provides key market data on the Germany Respiratory Devices market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Humidifiers, Nebulizers, NonInvasive Ventilation Masks Circuits, Oxygen Concentr...

Clinical Trial Launches to Develop Breath Test for Multiple Cancers

Cancer Research UK recruits first patients in trial to improve the early detection and diagnosis of different cancer types. Study will use Owlstone Medical’s Breath Biopsy platform to identify breath biomarkers to detect and differentiate early-stage disease. Study will recruit 1,500 patients at Addenbrooke’s Hospital, Cambridge. Owlstone Medical, a global diagnostics company...

A simple multifunctional tool for integrated care of COPD

Chronic obstructive pulmonary disease (COPD) affects around 1.2 million people in the UK and has an impact across NHS services[1]. Patients frequently present acutely in the emergency department with an exacerbation of the disease and rely heavily on community ...

Conversio Health Announces Leadership Transition and Appointment of Tom Frosheiser as CEO and Member of the Board of Directors

Conversio Health welcomes accomplished healthcare executive Tom Frosheiser THE WOODLANDS, Texas (PRWEB) January 16, 2019 Tom Frosheiser has joined Conversio Health as CEO and member of the company’s board of directors. Mr. Frosheiser succeeds co-founder and former CEO, Kirk Clove who will remain on Conversio Health’s board of directors and serve as a strategic advisor to the company. Mr. Clov...

Continuous pulse oximetry and respiratory rate trends predict short-term respiratory and growth outcomes in premature infants

Clinical impact of body composition phenotypes in patients with COPD: a retrospective analysis

BioPharm updates 01/14: $AIMT govt shutdown delays BLA $VRNA COPD fail -30% $BPTH $ALNY $STML offerings $ASLN gastric fail $PFE Tafamidis Jul/Nov PDUFA $NBRV PDUFA 4/30(brought fwd) $EXEL Cabometyx HCC FDA Approval $VVUS +38% Pipe updates $VERU $HTBX htt

BioPharm updates 01/14: $AIMT govt shutdown delays BLA $VRNA COPD fail -30% $BPTH $ALNY $STML offerings $ASLN gastri

Philips realigns three reporting segments

The most notable changes are the shift of the Sleep & Respiratory Care business from the Personal Health segment to the renamed Connected Care segment and the shift The post Philips realigns three reporting segments appeared first on Compelo Medical Devices.

Verona Pharma's ensifentrine fails to hit main goal of mid-stage COPD study https://www.firstwordpharma.com/node/1618110  $VRNA $VRP

Verona Pharma's ensifentrine fails to hit main goal of mid-stage COPD study https://www.firstwordpharma.com/node/1618110  $VRNA $VRP

$VRNA Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment https://globenewswire.com/news-release/2019/01/14/1690787/0/en/Verona-Pharma-Reports-Encouragi

$VRNA Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment https://globenewswire.com/news-release/2019/01/14/1690787/0/en/Verona-Pharma-Reports-Encouraging-Top-Line-Data-from-Three-Day-Phase-2-Trial-Evaluating-Nebulized-Ensifentrine-RPL554-on-Top-of-Dual-Bronchodilator-Therapy-for-COPD-Maintenan...

MICROBIOTE NASAL : Pourquoi le premier rhume de bébé peut durer

Le premier rhume de bébé peut durer plus longtemps, pourquoi ?  L’analyse des bactéries présentes dans le nez du bébé ou microbiote nasal, pourrait permettre d’expliquer des durées plus longues de récupération, révèle cette étude d’une équipe présentée dans l’European Respiratory Journal : ainsi, les bébés qui ont une grande variété de bactéries dans leur nez […...

A physician’s New Year’s resolutions

2019 is here. I started my year by doing an urgent care shift on New Year’s day.  It was not quite as busy as I expected; most of the shifts I’ve done around the holidays were high-volume, with lots of flu, other respiratory infections, and lacerations sustained while cooking holiday meals.  New Year’s day was […] Find jobs at Careers by KevinMD.com. Search thousands of...

Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Adult Respiratory Distress Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Adult Respiratory Distress Syndrome. Report inclu...

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and triple COPD therapy Investment community conference call scheduled for 8 am EST on Monday, January 14, 2019 LONDON, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical com...

FDA Approves Record-Breaking 59 Novel Drugs in 2018

Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

Circassia Pharmaceuticals Plc CIR Medical Equipment Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryCircassia Pharmaceuticals plc Circassia develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company's marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive ...

Top Acupuncture Now Treating Respiratory Diseases at its Houston Clinic

An industry leader in natural health has expanded its services. HOUSTON (PRWEB) January 11, 2019 According to research, acupuncture can quickly and effectively treat sinusitis, allergy, and asthma symptoms, and thanks to Top Acupuncture, people are now able to receive the respiratory treatment they need at its Houston clinic. “We don’t just treat the symptoms or diseases. We focus on the root...

Gut Microbiome Protects Lab Mice Against Arsenic in Water

ArticleChronic low-dose exposure to arsenic has been implicated in respiratory problems, cardiovascular disease, diabetes, and numerous forms of cancer.

Correction to: Non-prescribed sale of antibiotics for acute childhood diarrhea and upper respiratory tract infection in community pharmacies: a 2 phase mixed-methods study

The original article [1] contains a minor omission.

Aposense unit to raise $20m from Len Blavatnik

Sirvir will develop treatments for infectious diseases in the respiratory system.

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Respiratory market research data and corporate reports here